| Literature DB >> 32005180 |
Euan N Paterson1, Meera L Ravindran1, Kayleigh Griffiths1, Claire A Le Velly1, Chris C Cardwell1, Rachel V McCarter1, Patrick Nicol1, Jay K Chhablani2, Mohammed Abdul Rasheed3, Kiran Kumar Vupparaboina3, Thomas J MacGillivray4, Mark Harbinson5, Alexander P Maxwell1, Ruth E Hogg1, Gareth J McKay6.
Abstract
BACKGROUND: Tissue derived biomarkers may offer utility as indicators of accumulated damage. Reduced thickness of retinal neuronal tissue and the vascular choroid have previously been associated with vascular damage and diabetes. We evaluated associations between retinal thickness, retinal microvascular and choroidal measures, and renal function in a population with a high burden of comorbidity.Entities:
Keywords: Choroid; Choroidal vascularity index; Choroidal volume; Chronic kidney disease; Renal function; Retina; Retinal microvasculature; Retinal thickness
Mesh:
Substances:
Year: 2020 PMID: 32005180 PMCID: PMC6995224 DOI: 10.1186/s12882-019-1679-1
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.388
Fig. 1Retinal images and grid positions: a shows an image of the retina en face. b shows a cross-sectional image with differentiation of the retinal layers using the HAYEX software. The cross-section of the retina represents the layers directly behind the green line bisecting the en face image in panel A. The cross hairs in the left hand panel indicate the location of the foveal dip which can be seen as a depression in the centre of the image in panel B. c indicates the approximate position and size of the ETDRS grid used for reporting retinal thickness. Segment F is centred over the fovea. The annulus proximal to the fovea (annulus 1) comprises segments; S1 = superior 1; N1 = nasal 1; I1 = inferior 1; T1 = temporal 1. The annulus distal to the fovea comprises segments; S2 = superior 2; N2 = nasal 2; I2 = inferior 2; T2 = temporal 2. d highlights the locations where the ETDRS grid segments bisect the retinal image shown in panel B
Participant characteristics
| Variable | Population value |
|---|---|
| Age, years, mean (SD) | 65.3 (9.5) |
| Female, n (%) | 106 (44) |
| eGFR, ml/min/1.73m2, mean (SD) | 67 (25) |
| Weight, Kg, mean (SD) | 89.0 (20.1) |
| BMI, kg/m2, mean (SD) | 31.0 (6.4) |
| Hypertension, n (%) | 157 (65) |
| SBP, mmHg, mean (SD) | 136 (22) |
| DBP, mmHg, mean (SD) | 81 (13) |
| MABP (1/3 SBP + 2/3 DBP), mmHg, mean (SD) | 99 (13) |
| HbA1c mean, mmol/mol, (SD) | 53 (18) |
| Total Cholesterol, mean, mmol/L (SD) | 3.92 (1.18) |
| HDL, mean, mmol/L (SD) | 1.33 (0.45) |
| LDL, mean, mmol/L (SD) | 2.28 (0.97) |
| Troponin, mean, mmol/L (SD) | 17.8 (28.9) |
| CRP, mean, mmol/L (SD) | 9.5 (35.6) |
| Pack Years, mean (SD) | 39.8 (35.0) |
| CVD, n (%) | 100 (41.5) |
| Diabetes mellitus, n (%) | 93 (39) |
| Type 1, n (%) | 13 (5) |
| Type 2, n (%) | 80 (33) |
| Insulin, n (%) | 29 (31) |
| Previous CVA, n (%) | 19 (8) |
| Antihypertensives, n (%) | 83 (35) |
| Hypoglycaemics, n (%) | 68 (29) |
| Statins, n (%) | 164 (69) |
| Diuretics, n (%) | 63 (27) |
| NSAIDs, n (%) | 12 (5) |
| Vitamin supplements, n (%) | 48 (20) |
| Rheumatoid arthritis, n (%) | 10 (9) |
| Hypertension treatment, n (%) | |
| None | 78 (33) |
| < 5 years | 54 (23) |
| 5–10 years | 38 (16) |
| > 10 years | 64 (27) |
| Smoking, n (%) | |
| Never | 119 (49) |
| Ex | 87 (36) |
| Current | 35 (15) |
| Alcohol, n (%) | |
| none | 134 (56) |
| 1–5 units | 38 (16) |
| 6–10 units | 28 (12) |
| 15–20 units | 25 (10) |
| > 25 units | 12 (5) |
| QRISK2 score, n (%) | |
| 1 | 38 (34) |
| 2 | 35 (31) |
| 3 | 38 (34) |
SD Standard deviation, eGFR estimated glomerular filtration rate, SBP Systolic blood pressure, DBP Diastolic blood pressure, MABP Mean arterial blood pressure, HbA1c Glycated haemoglobin A1c, HDL High density lipoprotein, LDL Low density lipoprotein, CRP C reactive protein, CVD Cardiovascular disease, CVA Cerebrovascular accident, NSAIDs Non-steroidal anti-inflammatory drugs
Mean retinal, inner retinal and outer retinal thickness values for CKD stages 1–2, 3, and 4–5
| ETDRS segment | Right eye | Left eye | ||||||
|---|---|---|---|---|---|---|---|---|
| CKD stages 1–2 | CKD stage 3 | CKD stage 4–5 | ANOVA | CKD stages 1–2 | CKD stage 3 | CKD stage 4–5 | ANOVA | |
| Mean thickness μm (SD) | Mean thickness | Mean thickness μm (SD) | p | Mean thickness μm (SD) | Mean thickness | Mean thickness μm (SD) | p | |
| Full retinal thickness | ||||||||
| N1 | 342 (17) A | 339 (21) A | 324 (27) B | < 0.001* | 343 (22) A | 341 (26) A | 327 (28) B | 0.004* |
| S1 | 337 (18) A | 336 (20) A | 320 (26) B | < 0.001* | 340 (20) A | 336 (22) A | 321 (28) B | < 0.001* |
| T1 | 326 (17) | 324 (16) | 317 (48) | 0.14 | 328 (19) A | 325 (19) A | 313 (38) B | 0.005* |
| I1 | 336 (17) A | 332 (19) A | 319 (28) B | < 0.001* | 337 (21) A | 333 (19) A | 318 (27) B | < 0.001* |
| Inner Retinal Layer | ||||||||
| N1 | 261 (17) A | 258 (19) A | 244 (26) B | < 0.001* | 262 (21) A | 257 (19) B | 248 (30) B | 0.01* |
| S1 | 257 (17) A | 256 (19) A | 241 (25) B | < 0.001* | 260 (20) A | 255 (19) A | 243 (30) B | 0.001* |
| T1 | 246 (16) | 244 (15) | 238 (48) | 0.19 | 248 (18) A | 245 (18) A | 235 (38) B | 0.01* |
| I1 | 257 (17) A | 253 (18) A | 240 (28) B | < 0.001* | 258 (20) A | 254 (16) A | 241 (27) B | < 0.001* |
| Outer Retinal Layer | ||||||||
| N1 | 81 (3) | 81 (4) | 80 (3) | 0.47 | 81 (3) | 83 (11) | 80 (3) | 0.06 |
| S1 | 80 (3) | 80 (4) | 79 (3) | 0.45 | 80 (3) | 81 (7) | 79 (3) | 0.08 |
| T1 | 80 (3) | 80 (4) | 79 (3) | 0.29 | 80 (3) | 80 (3) | 79 (3) | 0.35 |
| I1 | 79 (3) | 79 (4) | 79 (4) | 0.91 | 79 (3) | 80 (6) | 78 (4) | 0.15 |
ETDRS Early Treatment Diabetic Retinopathy Study, OR Odds ratio, SD Standard deviation, CI Confidence interval, F Fovea, S1 Superior segment 1, N1 Nasal segment 1, I1 Inferior segment 1, T1 Temporal segment 1. A, B and C indicate groups which are significantly different from each other according to SNK test
Odds ratios from multinomial logistic regression models for CKD stage 3 and stages 4–5 per μm increase in thickness of the full retina, inner retina and outer retina
| ETDRS segment | Right eye | Left eye | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CKD stage 3 (vs. stage 1–2) | CKD stage 4–5 (vs. stage 1–2) | CKD stage 3 (vs. stage 1–2) | CKD stage 4–5 (vs. stage 1–2) | |||||||||
| OR | 95% CI | p | OR | 95% CI | p | OR | 95% CI | p | OR | 95% CI | p | |
| Full retinal thickness | ||||||||||||
| N1 | 1.00 | (0.97, 1.02) | 0.89 | 0.97 | (0.94, 0.99) | 0.02* | 1.00 | (0.98, 1.01) | 0.70 | 0.98 | (0.95, 1.00) | 0.03* |
| S1 | 1.00 | (0.98, 1.03) | 0.76 | 0.97 | (0.94, 0.99) | 0.01* | 1.00 | (0.98, 1.01) | 0.69 | 0.97 | (0.95, 0.99) | 0.01* |
| T1 | 1.00 | (0.98, 1.02) | 0.80 | 0.99 | (0.97, 1.01) | 0.33 | 1.00 | (0.98, 1.02) | 0.83 | 0.98 | (0.96, 1.00) | 0.08 |
| I1 | 1.00 | (0.97, 1.02) | 0.87 | 0.97 | (0.95, 1.00) | 0.02* | 1.00 | (0.98, 1.01) | 0.73 | 0.97 | (0.94, 0.99) | 0.01* |
| Inner Retinal Layer | ||||||||||||
| N1 | 1.00 | (0.97, 1.02) | 0.70 | 0.97 | (0.94, 0.99) | 0.01* | 0.99 | (0.97, 1.01) | 0.32 | 0.98 | (0.95, 1.00) | 0.03* |
| S1 | 1.00 | (0.98, 1.03) | 0.87 | 0.97 | (0.94, 0.99) | 0.01* | 0.99 | (0.98, 1.01) | 0.47 | 0.97 | (0.95, 0.99) | 0.01* |
| T1 | 1.00 | (0.98, 1.02) | 0.92 | 0.99 | (0.96, 1.01) | 0.34 | 1.00 | (0.98, 1.01) | 0.71 | 0.98 | (0.96, 1.00) | 0.09 |
| I1 | 1.00 | (0.97, 1.02) | 0.80 | 0.97 | (0.94, 0.99) | 0.02* | 0.99 | (0.97, 1.01) | 0.47 | 0.97 | (0.94, 0.99) | 0.01* |
| Outer Retinal Layer | ||||||||||||
| N1 | 1.08 | (0.96, 1.22) | 0.22 | 1.01 | (0.86, 1.18) | 0.93 | 1.12 | (0.99, 1.28) | 0.08 | 1.00 | (0.85, 1.17) | 0.96 |
| S1 | 1.07 | (0.93, 1.22) | 0.34 | 1.00 | (0.84, 1.18) | 0.96 | 1.08 | (0.96, 1.21) | 0.20 | 0.97 | (0.83, 1.13) | 0.68 |
| T1 | 1.10 | (0.96, 1.25) | 0.19 | 1.01 | (0.84, 1.20) | 0.94 | 1.08 | (0.93, 1.26) | 0.31 | 0.99 | (0.82, 1.18) | 0.90 |
| I1 | 1.05 | (0.92, 1.21) | 0.46 | 1.05 | (0.89, 1.25) | 0.54 | 1.09 | (0.96, 1.23) | 0.18 | 1.02 | (0.88, 1.18) | 0.82 |
ETDRS Early Treatment Diabetic Retinopathy Study, OR Odds ratio, SD Standard deviation, CI Confidence interval, F Fovea, S1 Superior segment 1, N1 Nasal segment 1, I1 Inferior segment 1, T1 Temporal segment 1.*significant values. Adjustment for age, mean arterial blood pressure, diabetes status, low-density lipoprotein, body mass index, and sex
Odds ratios from multinomial logistic regression models for CKD stage 3 and stages 4–5 per μm increase in thickness of retinal layers supplied by the retinal microvasculature
| ETDRS segment | Right eye | Left eye | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CKD stage 3 (vs. stage 1–2) | CKD stage 4–5 (vs. stage 1–2) | CKD stage 3 (vs. stage 1–2) | CKD stage 4–5 (vs. stage 1–2) | |||||||||
| OR | 95% CI | p | OR | 95% CI | p | OR | 95% CI | p | OR | 95% CI | p | |
| Nerve fibre layer | ||||||||||||
| N1 | 0.99 | (0.86, 1.14) | 0.88 | 0.88 | (0.74, 1.05) | 0.15 | 1.01 | (0.90, 1.13) | 0.93 | 1.00 | (0.90, 1.11) | 0.95 |
| S1 | 1.05 | (0.96, 1.16) | 0.27 | 1.00 | (0.90, 1.11) | 0.97 | 1.03 | (0.94, 1.13) | 0.52 | 0.99 | (0.89, 1.10) | 0.85 |
| T1 | 0.83 | (0.64, 1.06) | 0.14 | 1.04 | (0.96, 1.13) | 0.35 | 0.95 | (0.77, 1.17) | 0.63 | 1.14 | (0.96, 1.36) | 0.14 |
| I1 | 0.97 | (0.87, 1.08) | 0.58 | 0.94 | (0.84, 1.06) | 0.31 | 1.02 | (0.92, 1.13) | 0.70 | 1.00 | (0.90, 1.11) | 0.94 |
| Ganglion cell layer | ||||||||||||
| N1 | 1.02 | (0.96, 1.09) | 0.48 | 0.93 | (0.87, 1.00) | 0.04* | 1.00 | (0.94, 1.07) | 0.98 | 0.94 | (0.87, 1.01) | 0.08 |
| S1 | 1.02 | (0.95, 1.09) | 0.60 | 0.92 | (0.86, 0.99) | 0.02* | 1.01 | (0.94, 1.09) | 0.75 | 0.95 | (0.88, 1.03) | 0.18 |
| T1 | 1.01 | (0.94, 1.08) | 0.87 | 0.89 | (0.82, 0.97) | 0.01* | 1.01 | (0.95, 1.07) | 0.74 | 0.93 | (0.87, 0.99) | 0.02* |
| I1 | 1.02 | (0.95, 1.10) | 0.57 | 0.90 | (0.83, 0.96) | 0.004* | 1.03 | (0.96, 1.10) | 0.47 | 0.90 | (0.84, 0.97) | 0.004* |
| Inner plexiform layer | ||||||||||||
| N1 | 1.01 | (0.92, 1.11) | 0.83 | 0.91 | (0.82, 1.00) | 0.04* | 0.99 | (0.91, 1.09) | 0.90 | 0.90 | (0.82, 1.00) | 0.04* |
| S1 | 1.01 | (0.92, 1.12) | 0.78 | 0.89 | (0.80, 0.99) | 0.03* | 0.99 | (0.89, 1.10) | 0.81 | 0.88 | (0.78, 0.99) | 0.03* |
| T1 | 1.00 | (0.90, 1.11) | 0.96 | 0.87 | (0.78, 0.98) | 0.02* | 1.03 | (0.93, 1.13) | 0.61 | 0.89 | (0.80, 0.99) | 0.03* |
| I1 | 1.01 | (0.90, 1.12) | 0.92 | 0.85 | (0.76, 0.96) | 0.01* | 1.02 | (0.92, 1.14) | 0.66 | 0.82 | (0.73, 0.93) | 0.002* |
| Inner nuclear layer | ||||||||||||
| N1 | 0.91 | (0.82, 1.02) | 0.10 | 0.9 | (0.79, 1.02) | 0.11 | 0.90 | (0.81, 1.01) | 0.07 | 0.96 | (0.86, 1.06) | 0.42 |
| S1 | 0.92 | (0.83, 1.02) | 0.11 | 0.9 | (0.80, 1.01) | 0.08 | 0.92 | (0.84, 1.01) | 0.09 | 0.88 | (0.79, 0.97) | 0.01* |
| T1 | 0.91 | (0.80, 1.03) | 0.14 | 0.87 | (0.75, 1.00) | 0.06 | 0.93 | (0.83, 1.03) | 0.17 | 0.88 | (0.78, 0.99) | 0.03* |
| I1 | 0.96 | (0.86, 1.06) | 0.42 | 0.96 | (0.84, 1.08) | 0.49 | 0.93 | (0.84, 1.03) | 0.16 | 0.89 | (0.79, 1.00) | 0.06 |
ETDRS Early Treatment Diabetic Retinopathy Study, OR Odds ratio, SD Standard deviation, CI Confidence interval, F Fovea, S1 Superior segment 1, N1 Nasal segment 1, I1 Inferior segment 1, T1 Temporal segment 1.*significant values. Adjustment for age, mean arterial blood pressure, diabetes status, low-density lipoprotein, body mass index, and sex
Odds ratios from multinomial logistic regression models for CKD stage 3 and stages 4–5 per μm increase in thickness of retinal layers supplied by the choroidal vasculature
| ETDRS segment | Right eye | Left eye | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CKD stage 3 (vs. stage 1–2) | CKD stage 4–5 (vs. stage 1–2) | CKD stage 3 (vs. stage 1–2) | CKD stage 4–5 (vs. stage 1–2) | |||||||||
| OR | 95% CI | p | OR | 95% CI | p | OR | 95% CI | p | OR | 95% CI | p | |
| Outer plexiform layer | ||||||||||||
| N1 | 1.03 | (0.97, 1.10) | 0.33 | 1.03 | (0.96, 1.11) | 0.45 | 1.00 | (0.94, 1.07) | 0.89 | 1.00 | (0.93, 1.08) | 0.94 |
| S1 | 1.02 | (0.96, 1.09) | 0.46 | 0.95 | (0.86, 1.04) | 0.26 | 1.00 | (0.95, 1.06) | 0.93 | 0.93 | (0.87, 0.99) | 0.03* |
| T1 | 1.07 | (0.96, 1.20) | 0.22 | 0.93 | (0.81, 1.08) | 0.34 | 1.11 | (1.02, 1.22) | 0.02* | 1.01 | (0.90, 1.13) | 0.84 |
| I1 | 1.01 | (0.94, 1.08) | 0.78 | 1.05 | (0.98, 1.14) | 0.18 | 1.04 | (0.97, 1.12) | 0.24 | 1.08 | (1.01, 1.16) | 0.03* |
| Outer nuclear layer | ||||||||||||
| N1 | 0.98 | (0.94, 1.01) | 0.22 | 0.95 | (0.91, 1.00) | 0.05* | 0.99 | (0.96, 1.02) | 0.35 | 0.97 | (0.93, 1.01) | 0.10 |
| S1 | 0.99 | (0.95, 1.03) | 0.52 | 0.97 | (0.92, 1.02) | 0.23 | 0.99 | (0.97, 1.02) | 0.45 | 0.99 | (0.96, 1.03) | 0.61 |
| T1 | 1.00 | (0.96, 1.04) | 0.89 | 1.00 | (0.97, 1.04) | 0.78 | 0.98 | (0.94, 1.01) | 0.20 | 0.98 | (0.95, 1.02) | 0.42 |
| I1 | 0.99 | (0.95, 1.03) | 0.68 | 0.96 | (0.91, 1.01) | 0.10 | 0.96 | (0.92, 1.00) | 0.07 | 0.94 | (0.89, 0.98) | 0.01* |
| Retinal pigmented epithelium | ||||||||||||
| N1 | 1.02 | (0.80, 1.30) | 0.88 | 1.00 | (0.75, 1.35) | 0.98 | 1.21 | (0.96, 1.53) | 0.11 | 1.01 | (0.76, 1.35) | 0.93 |
| S1 | 1.09 | (0.84, 1.42) | 0.51 | 0.97 | (0.70, 1.35) | 0.87 | 1.13 | (0.91, 1.39) | 0.26 | 0.77 | (0.55, 1.07) | 0.11 |
| T1 | 1.04 | (0.80, 1.35) | 0.79 | 1.05 | (0.76, 1.44) | 0.78 | 1.09 | (0.84, 1.41) | 0.53 | 1.01 | (0.74, 1.38) | 0.96 |
| I1 | 0.94 | (0.74, 1.20) | 0.63 | 1.00 | (0.75, 1.34) | 0.99 | 1.09 | (0.91, 1.31) | 0.34 | 0.99 | (0.77, 1.29) | 0.96 |
ETDRS Early Treatment Diabetic Retinopathy Study, OR Odds ratio, SD Standard deviation, CI Confidence interval, F Fovea, S1 Superior segment 1, N1 Nasal segment 1, I1 Inferior segment 1, T1 Temporal segment 1.*significant values. Adjustment for age, mean arterial blood pressure, diabetes status, low-density lipoprotein, body mass index, and sex
Odds ratios for CKD stage 3 and stages 4–5 per standard deviation increase choroidal vascularity index (unit-less), Choroidal volume (mm3), AVR (unit-less), and fractal dimension
| Variable | CKD stage 3 (vs. stage 1–2) | CKD stage 4–5 (vs. stage 1–2) | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | p | OR | 95% CI | p | |
| Choroidal vascularity index | 1.37 | (0.80, 2.36) | 0.25 | 1.44 | (0.78, 2.67) | 0.25 |
| Choroidal Volume (mm3) | 0.90 | (0.55, 1.46) | 0.67 | 0.76 | (0.40, 1.44) | 0.40 |
| CRAE | 0.92 | (0.54, 1.55) | 0.75 | 0.66 | (0.35, 1.28) | 0.22 |
| CRVE | 0.66 | (0.41, 1.06) | 0.08 | 1.07 | (0.55, 2.07) | 0.85 |
| AVR | 1.67 | (1.01, 2.75) | 0.05* | 0.59 | (0.27, 1.26) | 0.17 |
| LogFractalDimCa1 | 1.05 | (0.62, 1.79) | 0.86 | 0.45 | (0.24, 0.84) | 0.01* |
| LogFractalDimCv1 | 0.94 | (0.58, 1.54) | 0.82 | 0.53 | (0.29, 0.94) | 0.03* |
CI Confidence interval, OR Odds ratio. *significant values. Adjustment for age, mean arterial blood pressure, diabetes status, low-density lipoprotein, body mass index, and sex